Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Johanna Mercier Sells 28,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock
04:56am, Friday, 20'th Feb 2026
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The shares were sold at an averag
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
10:01am, Thursday, 19'th Feb 2026
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
08:30am, Tuesday, 17'th Feb 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention port
Cookson Peirce & Co. Inc. Increases Holdings in Gilead Sciences, Inc. $GILD
06:02am, Saturday, 14'th Feb 2026
Cookson Peirce and Co. Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 249.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities
Gilead Sciences, Inc. $GILD Stock Holdings Reduced by Atria Investments Inc
03:30am, Saturday, 14'th Feb 2026
Atria Investments Inc trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 5.0% in the undefined quarter, according to the company in its most recent filing with the Securities an
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
10:51am, Friday, 13'th Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?
10:41am, Friday, 13'th Feb 2026
Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.
Focus on These 5 Stocks That Recently Hiked Dividends
09:15am, Friday, 13'th Feb 2026
NTES joins four peers in lifting dividends as resilient markets, rate-cut hopes and volatility spur investors toward steady income plays.
Caisse Des Depots ET Consignations Cuts Stock Holdings in Gilead Sciences, Inc. $GILD
06:21am, Thursday, 12'th Feb 2026
Caisse Des Depots ET Consignations lowered its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 17.0% in the undefined quarter, according to the company in its most recent 13F filing with the SEC.
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?
08:26pm, Wednesday, 11'th Feb 2026
Biotech leader Gilead Sciences (GILD) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales
11:15am, Wednesday, 11'th Feb 2026
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.
Gilead Sciences Stock Surges to Record Highs Amid Bull Notes
10:40am, Wednesday, 11'th Feb 2026
Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter
Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings
08:53am, Wednesday, 11'th Feb 2026
Gilead Sciences Inc. (NASDAQ: GILD) posted upbeat fourth-quarter earnings but issued weak fiscal 2026 guidance on Tuesday.
Breakfast News: First SaaS, Now Finance Hit By AI
07:30am, Wednesday, 11'th Feb 2026
AI makes move into tax planning, Shopify and Unity report this morning, and more
Advisors Asset Management Inc. Reduces Stock Holdings in Gilead Sciences, Inc. $GILD
04:08am, Wednesday, 11'th Feb 2026
Advisors Asset Management Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 17.4% in the undefined quarter, according to the company in its most recent Form 13F filing wit
